Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AG's Other Operating Expense for the
six
months ended in Jun. 2026 was $-4 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 was $-7 Mil.
Sandoz Group AG's quarterly Other Operating Expense
declined
from Jun. 2025 ($-3 Mil) to Dec. 2025 ($-3 Mil) and
declined
from Dec. 2025 ($-3 Mil) to Jun. 2026 ($-4 Mil).
Sandoz Group AG's annual Other Operating Expense
declined
from Dec. 2023 ($-8 Mil) to Dec. 2024 ($-10 Mil) but then
increased
from Dec. 2024 ($-10 Mil) to Dec. 2025 ($-6 Mil).
Sandoz Group AG Other Operating Expense Related Terms
Sandoz Group AG Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of $-7 Mil mean?
Sandoz Group AG (SDZXF) has a Other Operating Expense of $-7 Mil as of Jun. 2026. Other operating expenses that a company records on its income statement. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Other Operating Expense too high?
Sandoz Group AG's current Other Operating Expense is $-7 Mil. Overall, Sandoz Group AG has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Other Operating Expense compare to ZTS and UTHR?
Sandoz Group AG's Other Operating Expense of $-7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Other Operating Expense is $-7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (SDZXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $51.14, compared to a current price of $80.40 — trading 57.2% above its estimated fair value. The current Other Operating Expense is $-7 Mil. Sandoz Group AG's overall GF Score™ is 32/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current Other Operating Expense is $-7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandoz Group AG (SDZXF) Overvalued in 2026?
Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued.
The current stock price of $80.40 is trading 57.2% above its estimated GF Value™ of $51.14.
GuruFocus considers Sandoz Group AG to be Significantly Overvalued.
Key valuation signals for SDZXF:
Other Operating Expense: $-7 Mil
GF Value™: $51.14 vs. price of $80.40 (57.2% above fair value)
No single metric tells the full story. See the SDZXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sandoz Group AG is a Swiss generics and biosimilars pharmaceutical company, spun off from Novartis and listed independently in October 2023. It develops, manufactures, and markets off-patent medicines, with a portfolio spanning generic small molecules, complex injectables, value-added medicines, and biosimilars. Generics account for the large majority of sales, while biosimilars represent a growing share; Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, and the first US biosimilar, Zarxio, in 2015, and markets numerous biosimilar products with a substantial pipeline. Its customers include wholesalers, pharmacies, hospitals, and healthcare providers, and it operates across Europe, the United States, and other international markets. Revenue comes from product sales of generic and biosimilar pharmaceuticals, supported by manufacturing scale and a broad global commercial footprint.
32GF Score
Get the complete analysis for SDZXF
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDZXF has been successfully added to your 
